Ein Arzt berät einen Patienten (Symbolbild).
Freitag, 12.05.2017 15:05 von | Aufrufe: 28

Digipath, Inc. Announces Second Fiscal Quarter 2017 Results Highlighting 252% Increase in Revenue

Ein Arzt berät einen Patienten (Symbolbild). © TommL / Vetta / Getty Images https://www.gettyimages.de/

PR Newswire

LAS VEGAS, May 12, 2017 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), a growth oriented independent testing laboratory and media firm focused on the developing cannabis market, today announced financial and operating results for the three and six months ended March 31, 2017.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutrapharmaceutical products and services. (PRNewsFoto/Digipath, Inc.)

Second Fiscal Quarter 2017 Company Highlights

  • Ended quarter debt free with $429,425 of working capital, including $277,560 of cash on hand
  • Ended quarter with $497,049 of net sales, a quarter over quarter growth rate of approximately 21% from the previous quarter's net sales of $409,751, and a 252% increase on a year over year basis
  • Reduced our net loss by 50% over the comparative quarter, or $(222,597), from $(446,197) for the comparative three months ended March 31, 2016 to $(223,600) for the three months ended March 31, 2017, and improved our net loss for the first half of the fiscal year by $1,829,298, from $(2,179,058) for the comparative six months ended March 31, 2016 to $(349,760) for the six months ended March 31, 2017
  • Our Adjusted EBITDA for the quarter was $(58,428), compared to Adjusted EBITDA of $(86,637) for the previous fiscal quarter, an improvement of approximately 33% on a quarter over quarter basis
  • Our Adjusted EBITDA for the six months ended March 31, 2017 was $(145,065), compared to Adjusted EBITDA of $(624,337) for the comparative six months ended March 31, 2016, an improvement of approximately 77% on a year over year basis

The table below shows the preliminary results and key metrics (revenue data pertains to our Nevada lab operations only):






Quarterly Data


Quarterly Data


FYE September 30, 2016


ARIVA.DE Börsen-Geflüster

Kurse

-  
0,00%
DigiPath Chart

FYE September 30, 2017


Q1 2016


Q2 2016


Q3 2016


Q4 2016


Q1 2017


Q2 2017













Revenues (Thousands)

102


141


264


311


410


497

Lab Revenue Growth (%YOY)

-


-


-


-


301.18%


252.23%

Gross Profit Margins (%)

31.47%


39.51%


61.12%


60.81%


50.18%


55.54%

Return on Equity (%)

-10.23%


-31.39%


-80.77%


-164.43%


-10.23%


-15.27%

Return on Assets (%)

-7.02%


-24.05%


-60.29%


-112.20%


-8.79%


-14.92%













 

Adjusted EBITDA

We define Adjusted EBITDA as net earnings (loss) before (i) other income (expense), (ii) interest income, (iii) interest expense, (iv) bad debts, (v) depreciation and amortization, (vi) impairment of development costs, (vii) non-cash expenses relating to share based payments recognized under ASC Topic 718, (viii) gain on early extinguishment of debt, and (ix) equity in losses of unconsolidated entity. We believe the use of this non-GAAP financial measure provides useful information to investors regarding our current financial performance; however, Adjusted EBITDA does not represent, and should not be considered an alternative to GAAP measurements. Specifically, we believe Adjusted EBITDA results provide useful information to both management and investors by excluding certain income and expenses that our management believes are not indicative of our core operating results, we believe that non-GAAP financial measures have limitations and do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that Adjusted EBITDA should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. A reconciliation of Adjusted EBITDA to net loss is included below:


DIGIPATH, INC. AND SUBSIDIARIES

RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS

(Unaudited)










For the Three Months Ended


For the Six Months Ended


March 31,


March 31,


2017


2016


2017


2016









Net loss

$       (223,600)


$       (446,197)


$       (349,760)


$    (2,179,058)

Add back:








Other income

(106,000)


(12,000)


(260,000)


(30,000)

Interest income

(2,500)


(2,500)


(5,000)


(5,000)

Bad debts expense

6,804


13,250


23,754


303,021

Depreciation and amortization

61,420


61,138


123,073


122,230

Stock based compensation

205,448


74,111


322,868


183,921

Gain on early extinguishment of debt

-


-

Werbung

Mehr Nachrichten zur DigiPath Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News